phospho-IKK beta(Ser471)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 5398R
英文名称phospho-IKK beta(Ser471)
中文名称磷酸化碍叠抑制蛋白激酶β抗体
别 名IKK beta (phospho S471); IKK beta (phospho Ser471); p-IKK beta (Ser471); IKBKB; IKKI kappa B kinase 2; IKKβ; IKK β; I kappa B kinase beta; IkBKB; IKK 2; IKK B; IKK beta; IKK2; IKKB; Inhibitor of kappa light chain gene enhancer in B cells; Inhibitor of kappa light polypeptide gene enhancer in B cells; Inhibitor of kappa light polypeptide gene enhancer in B cells kinase beta; Inhibitor of nuclear factor kappa B kinase beta subunit; Inhibitor of nuclear factor kappa B kinase subunit beta; MGC131801; NFKBIKB; Nuclear factor NF kappa B inhibitor kinase beta; Nuclear factor of kappa light chain gene enhancer in B cells inhibitor; IKKB_HUMAN.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 **学 信号转导 转录调节因子 激酶和磷酸酶 细胞粘附分子
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-IKK beta(Ser471)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow, Rabbit,
产物应用ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量87kDa
细胞定位细胞核 细胞浆 细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human IKK beta around the phosphorylation site of Ser471:KN(p-S)MA
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-IKK beta(Ser471)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
IKK beta (I-Kappa-B kinase-beta) is a member of the IKK complex which is composed of IKK alpha, IKK beta, IKK gamma and IKAP. Phosphorylation of I-Kappa-B on a serine residue by the IKK complex frees NF-kB from I-Kappa-B and marks it for degradation via ubiquination. IKK beta has been shown to activate NF-kB and phosphorylate IKB alpha and beta. Phosphorylation of 2 sites at the activation loop of IKK beta is essential for activation of IKK by TNF and IL1. Once activated, IKK beta autophosphorylates which in turn decreases IKK activity and prevents prolonged activation of the inflammatory response. Additionally, IKK beta activity can also be regulated by MEKK1.
Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation.
Subunit:
Component of the I-kappa-B-kinase (IKK) core complex consisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits. The IKK core complex seems to associate with regulatory or adapter proteins to form a IKK-signalosome holo-complex. The IKK complex associates with TERF2IP/RAP1, leading to promote IKK-mediated phosphorylation of RELA/p65. Part of a complex composed of NCOA2, NCOA3, CHUK/IKKA, IKBKB, IKBKG and CREBBP. Part of a 70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14. Found in a membrane raft complex, at least composed of BCL10, CARD11, DPP4 and IKBKB. Interacts with SQSTM1 through PRKCZ or PRKCI. Forms an NGF-induced complex with IKBKB, PRKCI and TRAF6. May interact with MAVS/IPS1. Interacts with NALP2. Interacts with TICAM1. Interacts with Yersinia yopJ. Interacts with FAF1; the interaction disrupts the IKK complex formation. Interacts with ATM. Part of a ternary complex consisting of TANK, IKBKB and IKBKG. Interacts with NIBP; the interaction is direct. Interacts with ARRB1 and ARRB2. Interacts with TRIM21. Interacts with NLRC5; prevents IKBKB phosphorylation and kinase activity. Interacts with PDPK1.
Subcellular Location:
Cytoplasm. Nucleus. Membrane raft. Note=Colocalized with DPP4 in membrane rafts.
Tissue Specificity:
Highly expressed in heart, placenta, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis and peripheral blood.
Post-translational modifications:
Upon cytokine stimulation, phosphorylated on Ser-177 and Ser-181 by MEKK1 and/or MAP3K14/NIK as well as TBK1 and PRKCZ; which enhances activity. Once activated, autophosphorylates on the C-terminal serine cluster; which decreases activity and prevents prolonged activation of the inflammatory response. Phosphorylated by the IKK-related kinases TBK1 and IKBKE, which is associated with reduced CHUK/IKKA and IKBKB activity and NF-kappa-B-dependent gene transcription.
Acetylation of Thr-180 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the I-kappa-B pathway.
Ubiquitinated. Monoubiquitination involves TRIM21 that leads to inhibition of Tax-induced NF-kappa-B signaling. According to PubMed:19675099, 'Ser-163' does not serve as a monoubiquitination site. According to PubMed:16267042, ubiquitination on 'Ser-163' modulates phosphorylation on C-terminal serine residues. Monoubiquitination by TRIM21 is disrupted by Yersinia yopJ.
Similarity:
Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. I-kappa-B kinase subfamily.
Contains 1 protein kinase domain.
SWISS:
O14920
Gene ID:
3551
phospho-IKK beta(Ser471)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-IKK beta(Ser471)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 L3MBTL2 致死因子恶性脑瘤样蛋白2抗体
合格 L3MBTL4 致死因子恶性脑瘤样蛋白4抗体
合格 KCNH4 KCNH4蛋白抗体
合格 KCNH5 KCNH5蛋白抗体
合格 KCNK2 钾离子通道蛋白2抗体
合格 KCNMB2 钙激活钾通道蛋白β2抗体
合格 KCNN1 电导钙激活钾通道蛋白1抗体
合格 KCNQ3 电压门控钾通道亚基Kv7.3抗体
合格 KCNRG 钾离子通道调节蛋白KCNRG抗体
合格 HCN4 环化核苷酸调控阳离子通道蛋白亚型4
合格 KCNV1 电压门控钾通道亚基Kv8.1抗体
合格 合格 KCNV2 电压门控钾通道Kv8.2抗体
合格 KCT2 角质形成细胞相关跨膜蛋白2抗体
合格 KCTD1 钾离子通道多聚体结构域蛋白1抗体
合格 KCTD14 钾离子通道多聚体结构域蛋白14抗体
合格 KCTD17 钾离子通道多聚体结构域蛋白17抗体
合格 ZIP Kinase 凋亡相关蛋白激酶3抗体
合格 KCTD19 钾离子通道多聚体结构域蛋白19抗体
合格 KCTD6 KCTD6蛋白抗体
合格 合格 KCTD9 KCTD9蛋白抗体
合格 CANX 钙连蛋白抗体
合格 KDM6A 组蛋白去甲基化酶UTX抗体
合格 DcR2 诱捕受体2抗体
合格 Keratin 80 细胞角蛋白80抗体
合格 KGFLP1 成纤维细胞生长因子样蛋白1抗体
合格 BCOX1 乳腺癌过表达基因1蛋白抗体
合格 DELE DELE蛋白抗体
合格 DR5 肿瘤细胞调亡素/死亡受体5抗体
合格 KIAA0427 KIAA0427蛋白抗体
合格 KIAA0513 KIAA0513蛋白抗体
合格 KIAA0556 KIAA0556蛋白抗体